Reimbursed Care Access in Pakistan

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The Control of Narcotic Substances Act, 1997 provides the statutory basis for prohibition of psychotropic substances and makes possession, cultivation and trafficking illegal except where a license is granted for medical or scientific purposes; in practice there are no registered medical psilocybin products or routine clinical-access pathways in Pakistan. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There are no licensed MDMA products or national treatment programs using MDMA; law-enforcement operations and forensic reports indicate MDMA appears in illicit markets and is subject to seizures. #

Esketamine (marketed internationally as Spravato) is not registered as an approved product in Pakistan and is not part of public reimbursement programs; there is no documented national rollout or DRAP registration for esketamine as of current publicly available sources. Clinical and policy analyses addressing treatment-resistant depression in Pakistan note that esketamine is not widely available or registered locally and that its high cost and lack of mental‑health coverage would impede adoption even if registration occurred. #.

Because DRAP controls registration and import/marketing of pharmaceutical products, any esketamine product would require DRAP registration and accompanying local guidance to be used clinically; absent registration, esketamine could only be accessed in Pakistan through special import licences, named‑patient importation, or participation in an authorised clinical trial—paths that are rarely used for expensive novel psychotropic agents and would not be covered by public insurance. The national statutory framework for controlled substances (CNSA 1997) remains applicable to related substances and would require coordination between DRAP and law‑enforcement/ANF if any import exceptions were requested. # #.

Reimbursement: there is no evidence of public or private insurance coverage frameworks in Pakistan that reimburse esketamine for TRD; mental‑health services generally lack universal reimbursement and most advanced pharmacologic therapies are limited to private out‑of‑pocket payment. Local clinicians and health systems instead use generic ketamine in medical settings when indicated. #.

Ketamine is an accepted and widely used anesthetic and analgesic in Pakistan and is available commercially for medical use; it is regulated as a controlled medicine and subject to procurement, distribution and record‑keeping requirements under Pakistani law and DRAP oversight. However, the substance is also widely encountered in illicit diversion and seizures have been reported by the Anti‑Narcotics Force (ANF), demonstrating both legitimate medical supply and diversion risks. # #.

Clinical use and reimbursement context: In clinical practice in Pakistan ketamine is primarily supplied and used for anesthesia in hospitals and operating theatres with established supply chains; there is limited, mostly private‑sector off‑label use of ketamine infusions for severe or treatment‑resistant depression in tertiary/urban private facilities, but there is no standardized, nationally reimbursed ketamine‑for‑depression program. Public mental‑health financing is limited and advanced pharmacologic or procedural interventions for depression are generally paid out‑of‑pocket in private settings. A DRAP rapid alert and other regulatory notices also indicate vigilance about spurious or falsified ketamine products in the market, which factors into clinical procurement risk. # #.

Regional/state nuance: Health-care delivery and enforcement have provincial components (provincial drug control departments and policing) operating alongside federal ANF and DRAP authorities; availability of off‑label ketamine psychiatric services is concentrated in major cities and tertiary centres rather than rural provinces. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There are no registered medical DMT products or routine clinical access pathways in Pakistan. The CNSA provides the statutory framework governing psychotropic substances; enforcement is carried out by ANF and provincial authorities. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No evidence of legal medical access or registered products in Pakistan. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no regulatory pathway or registered ibogaine therapies in Pakistan. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The plants and extracts commonly used to prepare ayahuasca would fall under controlled psychotropic substances and there is no legally sanctioned religious‑use exemption or medical program permitting ayahuasca in Pakistan. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There are no registered mescaline products or permitted therapeutic programs in Pakistan. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Novel synthetic phenethylamines (2C family) are controlled in practice under Pakistan's psychotropic substances legislation and policed by ANF and provincial authorities; there is no legal therapeutic access. #